home
about us
member log-in
contact us

PRODUCTS
MUNICIPAL BONDS
INDEX FUNDS
- Total Asset Fund (TAF)
EVENTS
MARKET RESEARCH

Recent Quotes

View Full List

My Watchlist

Indicators

Markets:

Overview

News

Currencies

International

Treasuries

BeiGene, Ltd. - American Depositary Shares (NQ:BGNE)

184.71 UNCHANGED

Last Price Updated: 4:00 PM EST, Dec 31, 2024 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about BeiGene, Ltd. - American Depositary Shares

< Previous 1 2 3 4 5 6 7 8 9

...

16 17 Next >

Nurix Therapeutics (NASDAQ: NRIX) Stock Soars as Pivotal Phase 2 Study for Bexobrutideg Ignites Investor Confidence

October 22, 2025

San Francisco, CA – October 22, 2025 – Nurix Therapeutics (NASDAQ: NRIX) has captured significant market attention, with its stock experiencing a notable surge following the announcement of the...

Via MarketMinute

Lilly's Oncology Momentum Soars: Olomorasib Gains Breakthrough Status, Jaypirca Achieves Landmark Clinical Successes

September 19, 2025

Eli Lilly and Company (NYSE: LLY) is making significant waves in the oncology landscape with a series of major announcements concerning two of its innovative cancer therapies: Olomorasib and Jaypirca...

Via MarketMinute

A Glimpse Into The Expert Outlook On BeiGene Through 4 Analysts ↗

December 03, 2024

Via Benzinga

Why Is BeiGene Stock Trading Higher On Wednesday? ↗

November 27, 2024

BeiGene's Tevimbra receives EU approval for advanced ESCC and G/GEJ cancers, showing significant survival benefits in pivotal Phase 3 trials.

Via Benzinga

Expert Outlook: BeiGene Through The Eyes Of 4 Analysts ↗

October 22, 2024

Via Benzinga

Why Summit Therapeutics Rocketed Double-Digits Today ↗

April 23, 2025

Via The Motley Fool

Topics World Trade

BeiGene Receives Positive CHMP Opinion for TEVIMBRA® as a First-Line Treatment for Extensive-Stage Small Cell Lung Cancer

March 31, 2025

From BeiGene, Ltd.

Via Business Wire

TEVIMBRA Approved in U.S. for First-line Treatment of Gastric and Gastroesophageal Junction Cancers in Combination with Chemotherapy

December 27, 2024

From BeiGene, Ltd.

Via Business Wire

BeiGene to Change Nasdaq Ticker Symbol to “ONC” on January 2; Present at 43rd Annual J.P. Morgan Healthcare Conference

December 23, 2024

From BeiGene, Ltd.

Via Business Wire

Super Micro Computer, Adobe And Nucor Are Among Top Large Cap Losers Last Week (December 9-13): Are The Others In Your Portfolio? ↗

December 15, 2024

Large-cap stocks saw worst performance last week, including MongoDB, Applovin, CAVA, Super Micro Computer, FTAI, Adobe, Ferguson, Toll Brothers, BeiGene, Omnicom, and Nucor.

Via Benzinga

BeiGene Announces Global Licensing Agreement for MAT2A Inhibitor

December 12, 2024

From BeiGene, Ltd.

Via Business Wire

BeiGene Advances Leadership in CLL at ASH 2024 with New Data From Its Hematology Franchise Including BRUKINSA® and Novel Pipeline Assets

December 09, 2024

From BeiGene, Ltd.

Via Business Wire

BeiGene and CLL Society Partner to Advance Test Before Treat™ Campaign, Promoting Biomarker Testing to Improve Patient Outcomes in CLL

December 04, 2024

From BeiGene, Ltd.

Via Business Wire

BeiGene to Host Investor Webcast Highlighting Key Data from ASH and the San Antonio Breast Cancer Symposium on December 16, 2024

December 02, 2024

From BeiGene, Ltd.

Via Business Wire

European Commission Approves BeiGene’s TEVIMBRA for First-Line Treatment of Advanced/Metastatic Esophageal Squamous Cell Carcinoma and Gastric or Gastroesophageal Junction Cancer

November 27, 2024

From BeiGene, Ltd.

Via Business Wire

BeiGene to Present at Upcoming Investor Conferences

November 26, 2024

From BeiGene, Ltd.

Via Business Wire

BeiGene Announces Settlement of Litigation Against Generic Filer of BRUKINSA

November 19, 2024

From BeiGene, Ltd.

Via Business Wire

BeiGene Unveils Proposed Name Change to BeOne Medicines, Reaffirming Its Mission to Unite Global Community Against Cancer

November 14, 2024

From BeiGene, Ltd.

Via Business Wire

BeiGene Announces Third Quarter 2024 Financial Results and Corporate Updates

November 12, 2024

From BeiGene, Ltd.

Via Business Wire

BeiGene to Present at the Jefferies London Healthcare Conference

November 06, 2024

From BeiGene, Ltd.

Via Business Wire

BeiGene Highlights Innovative Hematology Portfolio Across B-cell Malignancies at ASH 2024

November 05, 2024

From BeiGene, Ltd.

Via Business Wire

BeiGene Mourns Death of Beloved Board Member Donald Glazer

October 28, 2024

From BeiGene, Ltd.

Via Business Wire

BeiGene Receives Positive CHMP Opinions for TEVIMBRA® as a First-Line Treatment for Advanced/Metastatic Gastric or Gastroesophageal Junction Cancer and Esophageal Squamous Cell Carcinoma

October 21, 2024

From BeiGene, Ltd.

Via Business Wire

BeiGene Highlights Waldenström’s Macroglobulinemia Innovation at IWWM 2024

October 16, 2024

From BeiGene, Ltd.

Via Business Wire

US Listed Chinese Stocks Dominate Another Week - Li Auto, JD.com Among Top 10 Large Cap Gainers Last Week (Sept 30-Oct 4): Are The Others In Your Portfolio? ↗

October 06, 2024

Best performing large-cap stocks in the past week were mostly USA listed Chinese stocks due to additional stimulus measures to boost China's economy.

Via Benzinga

Active Biotech Alert: FDA Approves 16 New Cancer Treatments as Global Cancer Rates Skyrocket

October 04, 2024

EQNX::TICKER_START (NASDAQ:ONCY),(TSX:ONC),(NYSE:ABBV),(NASDAQ:BGNE),(NASDAQ:HCM),(NASDAQ:ELVN) EQNX::TICKER_END

Via FinancialNewsMedia

Topics Artificial Intelligence

BeiGene Provides Update on FDA Advisory Committee Vote on Benefit-Risk Profile of PD-1 Inhibitors, including TEVIMBRA®, for Treatment of ESCC and Gastric/GEJ Cancers

September 26, 2024

From BeiGene, Ltd.

Via Business Wire

Global Oncology Innovator BeiGene Appoints Shalini Sharp to Board of Directors

September 26, 2024

From BeiGene, Ltd.

Via Business Wire

FDA Casts Doubt On Use Of Merck, Bristol Myers' PD-1 Cancer Drugs For Certain Type Of Gastric Cancer Patients ↗

September 25, 2024

The FDA's advisory committee is set to evaluate the use of PD-1 inhibitors in gastric cancer patients, focusing on the risks and benefits for those with varying PD-L1 levels, including low expressers.

Via Benzinga

Chinese Biotech BeiGene Labeled 'Unique Investment' As Analyst Confident In Lead Cancer Drug ↗

September 18, 2024

JMP Securities has initiated coverage on BeiGene highlighting the Chinese biotech company as a 'unique investment opportunity.' The firm's leading drug, Brukinsa (zanubrutinib), is emerging in the...

Via Benzinga

< Previous 1 2 3 4 5 6 7 8 9

...

16 17 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.

Home
About Us
Products
Municipal Bonds
Index Funds
Seminars & Events
Market Research
Contact Us
Member Section
Privacy Policy
Terms & Conditions
Security Notice
Customer Service

Securities offered through Purshe Kaplan Sterling Investments, member FINRA / SIPC, Headquartered at 80 State Street,
Albany, NY 12207
Purshe Kaplan Sterling Investments and Tamar Securities, LLC are not affiliated companies.
Tamar Securities, LLC is a Registered Investment Adviser. Advisory services are only offered to clients or prospective clients where Tamar Securities, LLC
and its representatives are properly licensed or exempt from licensure. Past performance is no guarantee of future returns. Investing involves risk and possible loss of principal capital.
No advice may be rendered by Tamar Securities, LLC unless a client service agreement is in place.

NOT FDIC INSURED. NOT BANK GUARANTEED. MAY LOSE VALUE, INCLUDING LOSS OF PRINCIPAL. NOT INSURED BY ANY STATE OR FEDERAL AGENCY.
Web development by IBCnet.com